DeepMed Research

The Case Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1826-01-01

Employees: 5K

Market Cap: -

Website: http://www.case.edu/cancer

Clinical Trials

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Phase 2

Active, not recruiting

Conditions: Glioblastoma

Interventions: Drug: Nivolumab
Drug: Standard Dose Bevacizumab
Drug: Low Dose Bevacizumab

First Posted Date: 2018-03-02

Last Posted Date: 2025-02-28

Lead Sponsor: David Peereboom

Target Recruit Count: 90

Registration Number: NCT03452579

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Acute Myeloid Leukemia
Myeloproliferative Neoplasm

Interventions: Drug: Azacitidine
Drug: Ascorbic acid

First Posted Date: 2018-01-11

Last Posted Date: 2021-08-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT03397173

Locations: 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction

Phase 2

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Liposomal Bupivacaine
Drug: Bupivacaine
Drug: Patient-Controlled Analgesia Pump
Drug: Oral Narcotic

First Posted Date: 2018-01-08

Last Posted Date: 2020-07-22

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT03393117

Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: Prostate cancer decision aid

First Posted Date: 2018-01-02

Last Posted Date: 2019-10-24

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT03387527

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Debulking Surgery in Ovarian Cancer

Not Applicable

Completed

Conditions: Malignant Neoplasm of Peritoneum
Malignant Neoplasm of Ovary
Malignant Neoplasm of Fallopian Tube

Interventions: Procedure: Diagnostic laparoscopy

First Posted Date: 2017-12-19

Last Posted Date: 2022-03-14

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT03378128

Locations: 🇺🇸
Atrium/Charlotte-Mecklenburg Hospital Authority, Charlotte, North Carolina, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Music Therapy and Hematopoietic Stem Cell Transplant

Not Applicable

Completed

Conditions: Hematopoietic Stem Cell Transplant

Interventions: Behavioral: Music Therapy
Behavioral: No Music Therapy

First Posted Date: 2017-12-19

Last Posted Date: 2019-08-01

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 56

Registration Number: NCT03378089

Locations: 🇺🇸
Cleveland Clinic, Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Melphalan
Drug: Thiotepa
Drug: Fludarabine

First Posted Date: 2017-11-14

Last Posted Date: 2025-03-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 39

Registration Number: NCT03342196

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Feasibility of a Social Media-based Weight Loss Program for Low Socioeconomic Status Individuals

Not Applicable

Completed

Conditions: Obesity

Interventions: Behavioral: Physical Activity
Behavioral: Diet
Behavioral: Social Support

First Posted Date: 2017-11-08

Last Posted Date: 2021-03-16

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 55

Registration Number: NCT03337230

Locations: 🇺🇸
Case Western Reserve Univeristy, Cleveland, Ohio, United States

Endoesophageal Brachytherapy for Patients With Esophageal Cancer

Not Applicable

Completed

Conditions: Esophageal Cancer

Interventions: Device: Endoesophageal Brachytherapy

First Posted Date: 2017-11-08

Last Posted Date: 2022-06-09

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 7

Registration Number: NCT03335813

Locations: 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Weston, Florida, United States

Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer

Phase 1

Withdrawn

Conditions: Metastatic Colorectal Cancer

Interventions: Radiation: yttrium-90 radioembolization
Drug: Phase Ib - nivolumab
Drug: Phase II - nivolumab

First Posted Date: 2017-10-11

Last Posted Date: 2018-02-27

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT03307603

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy